Journals / İstanbul Journal of Pharmacy / 2020 / Cilt: 50 - Sayı: 1

Development and validation of an HPLC method for determination of carbamazepine in human plasma and applications to a therapeutic drug monitoring study

Pages
6–15
Publication Date
2020-04-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In addition to that, female patient plasma-CBZ levels were found significantly higher than male plasma contents (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background and Aims: Carbamazepine (CBZ) is an antiepileptic drug, which is prescribed as a first-line drug for the treatment of partial and generalized tonic–clonic epileptic seizures.
📊
Key Findings & Data:The separation was conducted with a C18 reverse-phase column (150x3.9 mm, 5 µm) at 30°C, using a mobile phase prepared with 20 mM KH2PO4, acetonitrile and methanol (6:3:1, v/v/v) by isocratic elution.
💡
Conclusion & Impact:In addition to that, female patient plasma-CBZ levels were found significantly higher than male plasma contents (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Carbamazepine · plasma · therapeutic drug monitoring

Abstract

Background and Aims: Carbamazepine (CBZ) is an antiepileptic drug, which is prescribed as a first-line drug for the treatment of partial and generalized tonic–clonic epileptic seizures. The aim of this study was to develop and validate a simple, fast and reliable HPLC method for the determination of carbamazepine in human plasma. Methods: Chlorpromazine (CPR) was used as an internal standard. The separation was conducted with a C18 reverse-phase column (150x3.9 mm, 5 µm) at 30°C, using a mobile phase prepared with 20 mM KH2PO4, acetonitrile and methanol (6:3:1, v/v/v) by isocratic elution. Results: The method was linear between 0.5 and 40 µg/mL, determined by 10 individual calibration points. Total run time was ≤ 5 mins. Accuracy (RE%) values were determined between (-5.6) and 3.6%, and precision was determined at ≤4.2%. Limit of detection (LOD) was 0.04 µg/mL. The robustness test results of the method showed good values. Plasma CBZ of (n=30) those receiving CBZ quantities ranging from 0.2 to 1.2 g/day were measured with this method, and following analyses of their concentrations were found to be between 0.1 and 11.4 µg/mL (6.2±2.4 µg/mL). While all plasma sample analyses were applied properly, it was observed that 16 (53.3%) of the plasma samples had CBZ lower than the recommended range. In addition to that, female patient plasma-CBZ levels were found significantly higher than male plasma contents (p

🔖

Cite This Article

DURAL, E., ÇETİN, S., BOLAYIR, A., ÇİĞDEM, B. (2020). Development and validation of an HPLC method for determination of carbamazepine in human plasma and applications to a therapeutic drug monitoring study. İstanbul Journal of Pharmacy, Cilt: 50 - Sayı: 1, 6–15. https://ajindex.com/articles/41729

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Auer, M. E., Griesser, U. J., & Sawatzki J. (2003). Qualitative and quantitative study of polymorphic forms in drug formulations by near infrared FT-Raman spectroscopy. Journal of Molecular Structure, 661-662(1–3), 307–317. • Bertilsson, L. (1978). Clinical pharmacokinetics of carbamazepine. Clinical Pharmacokinetics, 3(2), 128-143. • Brunton, L. L., Knollmann, B. C., & Hilal-Dandan, R. (2018). Goodman & Gilman’s The pharmacological basis of therapeutics. New York, NY: McGraw Hill Medical. • Bugamelli F., Sabbioni, C., Mandrioli, R., Kenndler, E., Albani, F., & Raggi, M. A. (2002). Simultaneous analysis of six antiepileptic drugs and two selected metabolites in human plasma by liquid chromatography after solid-phase extraction. Analytica Chimica Acta, 472(1–2), 1–10. • Chbili, C., Hassine, A., Laouani, A., Amor, S. B., Nouira, M., Ammou, S. B., & Saguem, S. (2017). The relationship between pharmacokinetic parameters of carbamazepine and therapeutic response in epileptic patients. Archives of Medical Science, 13(2), 353–360. • Chen, C. H., & Lin, S. K. (2012). Carbamazepine treatment of bipolar disorder: A retrospective evaluation of naturalistic long-term outcomes. BMC Psychiatry, 12, 47. • Cottencin, O., Regnaut, N., Thevenon-Gignac, C., Thomas, P., Goudemand, M., Debruille, C., & Robert, H. (1995). Carbamazepine-fluvoxamine interaction. Consequences for the carbamazepine plasma level. Encephale, 21(2), 141–145. • Datar, P. A. (2015). Quantitative bioanalytical and analytical method development of dibenzazepine derivative, carbamazepine: A review. Journal of Pharmaceutical Analysis, 5(4), 213–222. • Deeb, S., McKeown, D. A., Torrance, H. J., Wylie, F. M., Logan, B. K, & Scott K. S. (2014). Simultaneous analysis of 22 antiepileptic drugs in postmortem blood, serum and plasma using LC-MS-MS with a focus on their role in forensic cases. Journal of Analytical Toxicology, 38(8), 485–494. • Domingues, D. S., Pinto, M. A. L., de Souza, I. D., Hallak, J. E., Crippa, J. A., & Queiroz, M. E. (2016). Determination of drugs in plasma samples by high-performance liquid chromatography-tandem mass spectrometry for therapeutic drug monitoring of schizophrenic patients. Journal of Analytical Toxicology, 40(1), 28–36. • Dordević, S., Kilibarda, V., & Stojanović, T. (2009). Determination of carbamazepine in serum and saliva samples by high performance liquid chromatography with ultraviolet detection. Vojnosanitetski pregled, 66(5), 347–352. • Ezzeldin, E., Shahat, A. A.,